Cardiology, Competitive Strategies, 2002 - Market Research Reports

Contents:

COMPETITIVE STRATEGIES IN CARDIOLOGY MEDICINE (2002)

TABLE OF CONTENTS

DISCLAIMER .......................................................................................................................................................... i
SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION......................................................................... i
METHODOLOGY OF INVESTIGATION.............................................................................................................. i
LIMITATIONS OF INVESTIGATION ................................................................................................................... i
COMPANY NAME CONVENTION..................................................................................................................... ii
EXECUTIVE SUMMARY....................................................................................................................................... iii
OVERALL PERSPECTIVE.................................................................................................................................... iii
OUTLOOK FOR CARDIOLOGY MARKET SEGMENTS.................................................................................. iii
ACS Disease ............................................................................................................................................. iii
Angina/Post AMI ...................................................................................................................................... iv
Arrhythmia ................................................................................................................................................ iv
Atherosclerosis.......................................................................................................................................... iv
Congestive Heart Failure (CHF) ................................................................................................................. v
Hypertension .............................................................................................................................................. v
Restenosis .................................................................................................................................................. v
Pipeline Discussion .................................................................................................................................... v
OUTLOOK FOR LEADING FIRMS IN CARDIOLOGY THERAPEUTICS ...................................................... ix
Abbott .................................................................................................................................................. xiv
AstraZeneca ............................................................................................................................................. xv
Aventis ................................................................................................................................................... xv
Bristol-Myers Squibb ............................................................................................................................... xv
GlaxoSmithKline .................................................................................................................................... xvi
Merck .................................................................................................................................................. xvi
Novartis ................................................................................................................................................. xvii
Pfizer ................................................................................................................................................. xvii
Pharmacia............................................................................................................................................... xvii
Roche ................................................................................................................................................xviii
Schering-Plough....................................................................................................................................xviii
Wyeth ................................................................................................................................................xviii
SECTION 1 COMPETITIVE BUSINESS ACTIVITY IN CARDIOLOGY MEDICINE................................... 1
1.1 INTRODUCTION ..................................................................................................................................... 1
1.2 OVERVIEW OF THE CARDIOLOGY MARKET.................................................................................... 3
1.2.1 Sales ................................................................................................................................................ 3
1.2.2 Incidence And Prevalence ................................................................................................................ 3
1.2.3 Macroeconomic drivers of the Market ............................................................................................. 4
1.2.4 Technology Platforms ...................................................................................................................... 5
1.3 ANALYSIS AND FORECAST OF THE ACS SECTOR ........................................................................ 16
1.3.1 Introduction and Pharmacological Management of ACS ............................................................... 16
1.3.2 Product Technology Evaluation and Forecast for ACS.................................................................. 16
1.3.3 Competitive Developments and implications in ACS .................................................................... 17
1.3.4 ACS Product Development Pipeline – Major Firms ...................................................................... 23
1.4 ANALYSIS AND FORECAST OF THE ANGINA SECTOR ................................................................ 25
1.4.1 Introduction and Pharmacological Management of Angina ........................................................... 25
1.4.2 Product Technology Evaluation and Forecast for Angina.............................................................. 25
1.4.3 Competitive Developments and implications in Angina ................................................................ 26
1.4.4 Angina Product Development Pipeline – Major Firms .................................................................. 30
1.5 ANALYSIS AND FORECAST OF THE ARRHYTHMIA SECTOR..................................................... 32
1.5.1 Introduction and Pharmacological Management of Arrhythmia .................................................... 32
1.5.2 Product Technology Evaluation and Forecast for Arrhythmia ....................................................... 32
1.5.3 Competitive Developments and implications in Arrhythmia ......................................................... 33
1.5.4 Arrhythmia Product Development Pipeline – Major Firms............................................................ 37
1.6 ANALYSIS AND FORECAST OF THE ATHEROSCLEROSIS SECTOR........................................... 39
1.6.1 Introduction and Pharmacological Management of Atherosclerosis .............................................. 39
1.6.2 Product Technology Evaluation and Forecast for Atherosclerosis................................................. 39
1.6.3 Competitive Developments and implications in Atherosclerosis .................................................. 40
1.6.4 Atherosclerosis Product Development Pipeline – Major Firms ..................................................... 46
1.7 ANALYSIS AND FORECAST OF THE CHF SECTOR ........................................................................ 48
1.7.1 Introduction and Pharmacological Management of Congestive Heart Failure............................... 48
1.7.2 Product Technology Evaluation and Forecast for CHF.................................................................. 48
1.7.3 Competitive Developments and implications in CHF ................................................................... 49
1.7.4 CHF Product Development Pipeline – Major Firms ...................................................................... 54
1.8 ANALYSIS AND FORECAST OF THE HYPERTENSION SECTOR.................................................. 56
1.8.1 Introduction and Pharmacological Management of Hypertension ................................................. 56
1.8.2 Product Technology Evaluation and Forecast for Hypertension .................................................... 56
1.8.3 Competitive Developments and implications in Hypertension ...................................................... 57
1.8.4 Hypertension Product Development Pipeline – Major Firms......................................................... 63
1.9 ANALYSIS AND FORECAST OF THE RESTENOSIS SECTOR ........................................................ 65
1.9.1 Introduction and Pharmacological Management of Restenosis...................................................... 65
1.9.2 Product Technology Evaluation and Forecast for Restenosis......................................................... 65
1.9.3 Competitive Developments and implications in Restenosis........................................................... 66
1.9.4 Restenosis Product Development Pipeline – Major Firms ............................................................. 69
SECTION 2 PROFILES OF LEADING FIRMS DEVELOPING AND/OR MARKETING CARDIOLOGY
THERAPEUTICS ........................................................................................................................ 71
2.1 ABBOTT.................................................................................................................................................. 71
2.1.1 Executive Summary ....................................................................................................................... 71
2.1.2 Current Strategic Position in Cardiology........................................................................................ 72
2.1.3 Cardiology Portfolio Performance.................................................................................................. 74
2.1.4 Product Development Activity in Cardiology ................................................................................ 75
2.1.5 Market Outlook in Cardiology ....................................................................................................... 76
2.1.6 Recent Events in Cardiology .......................................................................................................... 76
2.1.7 Cardiology and Related Collaborations.......................................................................................... 77
2.1.8 Cardiology Product Development Pipeline .................................................................................... 77
2.1.9 ACS Product Development Pipeline .............................................................................................. 80
2.1.10 Arrhythmia Product Development Pipeline.................................................................................... 80
2.1.11 Atherosclerosis Product Development Pipeline ............................................................................. 81
2.1.12 CHF Product Development Pipeline .............................................................................................. 82
2.1.13 Hypertension Product Development Pipeline................................................................................. 83
2.2 ASTRAZENECA..................................................................................................................................... 84
2.2.1 Executive Summary ....................................................................................................................... 84
2.2.2 Current Strategic Position in Cardiology........................................................................................ 84
2.2.3 Cardiology Portfolio Performance.................................................................................................. 86
2.2.4 Product Development Activity in Cardiology ................................................................................ 87
2.2.5 Market Outlook in Cardiology ....................................................................................................... 88
2.2.6 Recent Developments in Cardiology.............................................................................................. 88
2.2.7 Cardiology and Related Collaborations.......................................................................................... 89
2.2.8 Cardiology Product Development Pipeline .................................................................................... 90
2.2.9 ACS Product Development Pipeline .............................................................................................. 92
2.2.10 Atherosclerosis Product Development Pipeline ............................................................................. 93
2.2.11 CHF Product Development Pipeline .............................................................................................. 94
2.3 AVENTIS................................................................................................................................................. 96
2.3.1 Executive Summary ....................................................................................................................... 96
2.3.2 Current Strategic Position in Cardiology........................................................................................ 96
2.3.3 Cardiology Portfolio Performance.................................................................................................. 98
2.3.4 Product Development Activity in Cardiology ................................................................................ 99
2.3.5 Market Outlook in Cardiology ..................................................................................................... 100
2.3.6 Recent Events in Cardiology ........................................................................................................ 100
2.3.7 Cardiology and Related Collaborations........................................................................................ 101
2.3.8 Cardiology Product Development Pipeline .................................................................................. 102
2.3.9 ACS Product Development Pipeline ............................................................................................ 104
2.3.10 Angina Product Development Pipeline ........................................................................................ 105
2.3.11 Arrhythmia Product Development pipeline.................................................................................. 106
2.3.12 Atherosclerosis Product Development Pipeline ........................................................................... 107
2.3.13 CHF Product Development Pipeline ............................................................................................ 108
2.3.14 Hypertension Product Development Pipeline............................................................................... 109
2.3.15 Restenosis Product Development Pipeline ................................................................................... 110
2.4 BRISTOL-MYERS SQUIBB ................................................................................................................. 111
2.4.1 Executive Summary ..................................................................................................................... 111
2.4.2 Current Strategic Position in Cardiology Sales ............................................................................ 112
2.4.3 Cardiology Portfolio Performance................................................................................................ 114
2.4.4 Product Development Activity in Cardiology .............................................................................. 115
2.4.5 Market Outlook in Cardiology ..................................................................................................... 116
2.4.6 Recent Events in Cardiology ........................................................................................................ 117
2.4.7 Cardiology and Related Collaborations........................................................................................ 118
2.4.8 Cardiology Product Development Pipeline .................................................................................. 119
2.4.9 ACS Product Development Pipeline ............................................................................................ 123
2.4.10 Arrhythmia Product Development Pipeline.................................................................................. 125
2.4.11 Atherosclerosis Product Development Pipeline ........................................................................... 126
2.4.12 CHF Product Development Pipeline ............................................................................................ 127
2.4.13 Hypertension Product Development Pipeline............................................................................... 128
2.4.14 Restenosis Product Development Pipeline ................................................................................... 128
2.5 GLAXOSMITHKLINE .......................................................................................................................... 131
2.5.1 Executive Summary ..................................................................................................................... 131
2.5.2 Current Strategic Position in Cardiology...................................................................................... 131
2.5.3 Cardiology Portfolio Performance................................................................................................ 133
2.5.4 Product Development Activity in Cardiology .............................................................................. 134
2.5.5 Market Outlook In Cardiology ..................................................................................................... 134
2.5.6 Recent Events in Cardiology ........................................................................................................ 135
2.5.7 Cardiology and Related Collaborations........................................................................................ 135
2.5.8 Cardiology Product Development Pipeline .................................................................................. 136
2.5.9 ACS Product Development Pipeline ............................................................................................ 139
2.5.10 Atherosclerosis Product Development Pipeline ........................................................................... 139
2.5.11 CHF Product Development Pipeline ............................................................................................ 140
2.5.12 Hypertension Product Development Pipeline............................................................................... 141
2.6 MERCK ................................................................................................................................................. 143
2.6.1 Executive Summary ..................................................................................................................... 143
2.6.2 Current Strategic Position in Cardiology...................................................................................... 143
2.6.3 Cardiology Portfolio Performance................................................................................................ 146
2.6.4 Product Development Activity in Cardiology .............................................................................. 147
2.6.5 Market Outlook in Cardiology ..................................................................................................... 148
2.6.6 Recent Events in Cardiology ........................................................................................................ 149
2.6.7 Cardiology and Related Collaborations........................................................................................ 149
2.6.8 Cardiology Product Development Pipeline .................................................................................. 150
2.6.9 ACS Product Development Pipeline ............................................................................................ 152
2.6.10 Atherosclerosis Product Development Pipeline ........................................................................... 153
2.6.11 Hypertension Product Development Pipeline............................................................................... 154
2.7 NOVARTIS ........................................................................................................................................... 155
2.7.1 Executive Summary ..................................................................................................................... 155
2.7.2 Current Strategic Position in Cardiology...................................................................................... 155
2.7.3 Cardiology Portfolio Performance................................................................................................ 157
2.7.4 Product Development Activity in Cardiology .............................................................................. 158
2.7.5 Market Outlook in Cardiology ..................................................................................................... 159
2.7.6 Recent Events in Cardiology ........................................................................................................ 159
2.7.7 Cardiology and Related Collaborations........................................................................................ 160
2.7.8 Cardiology Product Development Pipeline .................................................................................. 161
2.7.9 ACS Product Development Pipeline ............................................................................................ 163
2.7.10 Angina Product Development Pipeline ........................................................................................ 163
2.7.11 Arrhythmia Product Development Pipeline.................................................................................. 164
2.7.12 CHF Product Development Pipeline ............................................................................................ 164
2.8 PFIZER .................................................................................................................................................. 166
2.8.1 Executive Summary ..................................................................................................................... 166
2.8.2 Current Strategic Position in Cardiology...................................................................................... 166
2.8.3 Cardiology Portfolio Performance................................................................................................ 168
2.8.4 Product Development Activity in Cardiology .............................................................................. 169
2.8.5 Market Outlook in Cardiology ..................................................................................................... 170
2.8.6 Recent Events In Cardiology........................................................................................................ 171
2.8.7 Cardiology and Related Collaborations........................................................................................ 171
2.8.8 Cardiology Product Development Pipeline .................................................................................. 171
2.8.9 ACS Product Development Pipeline ............................................................................................ 174
2.8.10 Atherosclerosis Product Development Pipeline ........................................................................... 175
2.8.11 CHF Product Development Pipeline ............................................................................................ 178
2.8.12 Restenosis Product Development Pipeline ................................................................................... 179
2.9 PHARMACIA........................................................................................................................................ 181
2.9.1 Executive Summary ..................................................................................................................... 181
2.9.2 Current Strategic Position in Cardiology...................................................................................... 181
2.9.3 Cardiovascular Portfolio Performance ......................................................................................... 183
2.9.4 Product Development Activity in Cardiology .............................................................................. 184
2.9.5 Market Outlook in Cardiology ..................................................................................................... 185
2.9.6 Recent Events in Cardiology ........................................................................................................ 185
2.9.7 Cardiology and Related Collaborations........................................................................................ 186
2.9.8 Cardiology Product Development Pipeline .................................................................................. 186
2.9.9 Atherosclerosis Product Development Pipeline ........................................................................... 189
2.9.10 CHF Product Development Pipeline ............................................................................................ 190
2.9.11 Hypertension Product Development Pipeline............................................................................... 190
2.9.12 Restenosis Product Development Pipeline ................................................................................... 191
2.10 ROCHE.................................................................................................................................................. 193
2.10.1 Executive Summary ..................................................................................................................... 193
2.10.2 Current Strategic Position in Cardiology...................................................................................... 193
2.10.3 Cardiology Portfolio Performance................................................................................................ 195
2.10.4 Product Development Activity in Cardiology .............................................................................. 196
2.10.5 Market Outlook in Cardiology ..................................................................................................... 197
2.10.6 Recent Events in Cardiology ........................................................................................................ 197
2.10.7 Cardiology and Related Collaborations........................................................................................ 198
2.10.8 Cardiology Product Development Pipeline .................................................................................. 198
2.10.9 ACS Product Development Pipeline ............................................................................................ 201
2.10.10 Atherosclerosis Product Development Pipeline........................................................................ 201
2.10.11 Hypertension Product Development Pipeline ........................................................................... 202
2.11 SCHERING-PLOUGH ........................................................................................................................... 203
2.11.1 Executive Summary ..................................................................................................................... 203
2.11.2 Current Strategic Position in Cardiology...................................................................................... 203
2.11.3 Cardiology Portfolio Performance................................................................................................ 205
2.11.4 Product Development Activity in Cardiology .............................................................................. 206
2.11.5 Market Outlook in Cardiology ..................................................................................................... 206
2.11.6 Recent Events in Cardiology ........................................................................................................ 207
2.11.7 Cardiology and Related Collaborations........................................................................................ 207
2.11.8 Cardiology Product Development Pipeline .................................................................................. 208
2.11.9 ACS Product Development Pipeline ............................................................................................ 211
2.11.10 Atherosclerosis Product Development Pipeline........................................................................ 211
2.11.11 Restenosis Product Development Pipeline ............................................................................... 212
2.12 WYETH................................................................................................................................................. 214
2.12.1 Executive Summary ..................................................................................................................... 214
2.12.2 Current Strategic Position in Cardiology...................................................................................... 214
2.12.3 Cardiology Portfolio Performance................................................................................................ 216
2.12.4 Product Development Activity in Cardiology .............................................................................. 217
2.12.5 Market Outlook in Cardiology ..................................................................................................... 218
2.12.6 Recent Events in Cardiology ........................................................................................................ 218
2.12.7 Cardiology and Related Collaborations........................................................................................ 219
2.12.8 Cardiology Product Development Pipeline .................................................................................. 220
2.12.9 ACS Product Development Pipeline ............................................................................................ 222
2.12.10 Atherosclerosis Product Development Pipeline........................................................................ 222
SECTION 3 EVALUATION OF THE LEADING FIRMS IN CARDIOLOGY MEDICINE......................... 225
3.1 COMPETENCY REQUIREMENTS FOR MARKET LEADERSHIP .................................................. 225
3.1.1 Competency Requirements........................................................................................................... 225
3.1.2 Competitive Analysis of Participating Manufacturers.................................................................. 230
3.2 FIVE-YEAR SUMMARY ANALYSIS AND EVALUATION OF CARDIOLOGY MARKET
LEADING STAKEHOLDERS............................................................................................................... 236

LIST OF FIGURES

Figure ES- 1 Leading Firms – Sales Change Analysis – 2001 to 2007 .............................................................. xiii
Figure ES- 2 Trends in Cardiology Portfolio Commitment................................................................................ xiv
Figure 1.1 Forecast for ACS by Technology Platform.................................................................................... 17
Figure 1.2 Trends in ACS Portfolio Commitment........................................................................................... 23
Figure 1.3 Product Development Timeline in ACS-Major Firms.................................................................... 24
Figure 1.4 Forecast for Angina by Technology Platform................................................................................ 26
Figure 1.5 Trends in Angina Portfolio Commitment....................................................................................... 30
Figure 1.6 Product Development Timeline in Angina ..................................................................................... 31
Figure 1.7 Forecast for Arrhythmia Management by Technology Platform.................................................... 33
Figure 1.8 Trends in Arrhythmia Portfolio Commitment ................................................................................ 37
Figure 1.9 Product Development Timeline in Arrhythmia .............................................................................. 38
Figure 1.10 Forecast for Atherosclerosis Management by Technology Platform.............................................. 40
Figure 1.11 New Product Launch Activity by Major Manufacturer by Year .................................................... 43
Figure 1.12 Trends in Atherosclerosis Portfolio Commitment .......................................................................... 46
Figure 1.13 Product Development Timeline in Atherosclerosis ........................................................................ 47
Figure 1.14 Forecast for CHF Management by Technology Platform .............................................................. 49
Figure 1.15 Trends in CHF Portfolio Commitment........................................................................................... 54
Figure 1.16 Product Development Timeline in CHF......................................................................................... 55
Figure 1.17 Forecast for Hypertension by Technology Platform....................................................................... 57
Figure 1.18 Trends in Hypertension Portfolio Commitment ............................................................................. 62
Figure 1.19 Product Development Timeline in Hypertension ........................................................................... 63
Figure 1.20 Forecast for Restenosis by Technology Platform........................................................................... 66
Figure 1.21 Trends in Restenosis Portfolio Commitment.................................................................................. 69
Figure 1.22 Product Development Timeline in Restenosis................................................................................ 70
Figure 2.1 Abbott’s Cardiology Technology Map........................................................................................... 78
Figure 2.2 Technology Utilization – Abbott vs. Industry ................................................................................ 79
Figure 2.3 Abbott’s Comparative Pipeline Distribution by Development Phase............................................. 79
Figure 2.4 AstraZeneca’s Cardiology Technology Map.................................................................................. 91
Figure 2.5 Technology Utilization – AstraZeneca vs. Industry ....................................................................... 91
Figure 2.6 AstraZeneca’s Comparative Pipeline Distribution by Development Phase.................................... 92
Figure 2.7 Technology Utilization – Aventis vs. Industry............................................................................. 103
Figure 2.8 Pipeline Distribution by Development Phase ............................................................................... 103
Figure 2.9 Bristol-Myers Squibb’s Cardiology Technology Map ................................................................. 120
Figure 2.10 Technology Utilization – Bristol-Myers Squibb vs. Industry....................................................... 121
Figure 2.11 Bristol-Myers Squibb’s Comparative Pipeline Distribution by Development Phase ................... 122
Figure 2.12 GlaxoSmithKline’s Cardiology Technology Map........................................................................ 137
Figure 2.13 GlaxoSmithKline’s Comparative Pipeline Distribution by Development Phase.......................... 138
Figure 2.14 Merck’s Cardiology Technology Map ......................................................................................... 151
Figure 2.15 Technology Utilization – Merck vs. Industry............................................................................... 151
Figure 2.16 Comparative Pipeline Distribution by Development Phase.......................................................... 152
Figure 2.17 Novartis’ Cardiology Technology Map........................................................................................ 161
Figure 2.18 Technology Utilization – Novartis vs. Industry ........................................................................... 162
Figure 2.19 Novartis’ Comparative Pipeline Distribution by Development Phase.......................................... 162
Figure 2.20 Pfizer’s Cardiovascular Technology Map .................................................................................... 172
Figure 2.21 Technology Utilization – Pfizer vs. Industry................................................................................ 173
Figure 2.22 Pfizer’s Comparative Pipeline Distribution by Development Phase ............................................ 173
Figure 2.23 Pharmacia’s Cardiovascular Technology Map............................................................................. 187
Figure 2.24 Technology Utilization – Pharmacia vs. Industry ........................................................................ 188
Figure 2.25 Pharmacia’s Comparative Pipeline Distribution by Development Phase..................................... 188
Figure 2.26 Roche’s Cardiology Technology Map.......................................................................................... 199
Figure 2.27 Technology Utilization – Roche vs. Industry............................................................................... 200
Figure 2.28 Roche’s Comparative Pipeline Distribution by Development Phase............................................ 200
Figure 2.29 Schering-Plough’s Cardiovascular Technology Map ................................................................... 209
Figure 2.30 Technology Utilization – Schering-Plough vs. Industry .............................................................. 210
Figure 2.31 Schering-Plough’s Comparative Pipeline Distribution by Development Phase ........................... 210
Figure 2.32 Wyeth’s Cardiovascular Technology Map ................................................................................... 220
Figure 2.33 Technology Utilization – Wyeth vs. Industry............................................................................... 221
Figure 2.34 Wyeth’s Comparative Pipeline Distribution by Development Phase ........................................... 221
Figure 3.1 Leading Firms – Sales Performance and Market Trends 2007..................................................... 238
Figure 3.2 Trends in Cardiology Portfolio Commitment............................................................................... 239

LIST OF TABLES

Table ES- 1 Cardiology Market Segment – Historic and Forecast Sales – ($Millions) ...................................... iii
Table ES- 2 Cardiology Product Development – Technology Platforms........................................................... vii
Table ES- 3 US Cardiology Historic/Forecast Sales, Sales Rank, Market Share – Leading Firms...................... x
Table ES- 4 US Cardiology Market – Major Stakeholder Lead Markets............................................................ xi
Table ES- 5 Summary Analysis Leading Stakeholders – Cardiology Therapeutics........................................... xii
Table 1.1 Cardiology Market Segment – Historic and Forecast Sales – (in $Millions) ................................... 3
Table 1.2 Adults Needing Prescriptions for Medicines to Reduce Cholesterol................................................ 4
Table 1.3 US Market Forecast for ACS by Therapy Class/Technology (in $Millions).................................. 18
Table 1.4 Technologies in Development for ACS – Major Firms.................................................................. 19
Table 1.5 New Product Launch Activity by Major Manufacturer by Year .................................................... 20
Table 1.6 US Historical and Forecast Sales for ACS by Leading Company (in $Millions)........................... 21
Table 1.7 Leading ACS Brands...................................................................................................................... 25
Table 1.8 US Market Forecast for Angina by Therapy Class/Technology (in $Millions).............................. 27
Table 1.9 Technologies in Development for Angina – Major Firms.............................................................. 27
Table 1.10 New Product Launch Activity for Angina by Major Manufacturer by Year.................................. 28
Table 1.11 US Historical and Forecast Angina Sales by Leading Company (in $Millions) ............................ 28
able 1.12 Leading Angina Brands.................................................................................................................. 32
Table 1.13 US Market Forecast for Arrhythmia by Therapy Class/Technology (in $Millions)....................... 34
Table 1.14 Technologies in Development for Arrhythmia-Major Firms.......................................................... 34
Table 1.15 New Product Launch Activity by Major Manufacturer by Year .................................................... 35
Table 1.16 US Historic and Forecast Arrhythmia Sales by Leading Company (in $Millions) ........................ 35
Table 1.17 Leading Arrhythmia Brands ........................................................................................................... 39
Table 1.18 US Market Forecast for Atherosclerosis by Therapy Class/Technology (in $Millions)................. 41
Table 1.19 Technologies in Development for Atherosclerosis – Major Firms................................................. 42
Table 1.20 US Historic and Forecast Atherosclerosis Sales by Leading Company (in $Millions) .................. 44
Table 1.21 Leading Atherosclerosis Brands..................................................................................................... 48
Table 1.22 US Market Forecast for CHF by Therapy Class/Technology (in $Millions).................................. 50
Table 1.23 Technologies in Development for CHF – Major Firms.................................................................. 51
Table 1.24 New Product Launch Activity by Major Manufacturer by Year .................................................... 51
Table 1.25 US Historic and Forecast CHF Sales by Leading Company (in $Millions) ................................... 52
Table 1.26 Leading CHF Brands...................................................................................................................... 56
Table 1.27 US Market Forecast for Hypertension by Therapy Class/Technology (in Millions)...................... 58
Table 1.28 Technologies In Development for Hypertension – Major Firms.................................................... 59
Table 1.29 New Product Activity by Company and Year to 2007 – Hypertension.......................................... 59
Table 1.30 US Historic and Forecast Sales for Hypertension by Leading Cardiology Company (in
$Millions) ...................................................................................................................................... 60
Table 1.31 Leading Hypertension Brands ........................................................................................................ 64
Table 1.32 US Market Forecast for Restenosis by Therapy Class/Technology (in $Millions) ........................ 66
Table 1.33 Technologies In Development for Restenosis – Major Firms ........................................................ 67
Table 1.34 New Product Launch Activity by Major Manufacturer by Year .................................................... 67
Table 1.35 US Historic and Forecast Sales for Restenosis by Leading Cardiology Company (in
$Millions) ...................................................................................................................................... 68
Table 1.36 Leading Restenosis Brands............................................................................................................. 70
Table 3.1 Manufacturer Drug Sales, Key Brands, and New Product Development Pipeline (in $Millions) 226
Table 3.2 Pharmaceutical Research & Development - Percent of Total Worldwide Sales (in $Millions) ... 227
Table 3.3 R&D Expenditures in Cardiology Therapeutics (in $Millions).................................................... 227
Table 3.4 Patent Expiration in Cardiovascular Disease Therapeutics– 2000-2007 (in $Millions)............... 228
Table 3.5 Business Development Activity in Cardiovascular Disease Therapeutics ................................... 229
Table 3.6 Leading Firms’ Sales Force Size.................................................................................................. 229
Table 3.7 US Cardiovascular Historic and Forecast Sales - Leading Firms (in $Millions).......................... 231
Table 3.8 US Cardiology Projected Sales – Leading Firms Ranked by 2007 $ (in $Millions) .................... 232
Table 3.9 US Cardiology Projected Sales – Leading Firms Ranked by 2001 to 2007 $ Sales Change (in
$Millions) .................................................................................................................................... 232
Table 3.10 US Cardiology Projected Sales – Leading Firms Ranked by 2001 to 2007 Percent Change (in
$Millions) .................................................................................................................................... 233
Table 3.11 US Cardiology Projected Sales – Leading Firms ......................................................................... 233
Table 3.12 New Product Launch Activity – Major Firms 1999-2007............................................................ 234
Table 3.13 Product Development Programs by Indication and Status ........................................................... 235
Table 3.14 Rank by Company Share of Cardiovascular Clinical Pipeline ..................................................... 236
Table 3.15 Summary Analysis Leading Stakeholders – Cardiovascular Therapeutics .................................. 236

LIST OF CHARTS

Chart 2.1.1 Abbott’s US Rx Sales Rank vs. Major Firms (in $Millions).......................................................... 72
Chart 2.1.2 Abbott’s Sales Rank In Cardiology (in $Millions)......................................................................... 72
Chart 2.1.3 Abbott’s Cardiology Share of Total US Sales................................................................................ 73
Chart 2.1.4 Abbott’s Historic Sales by Indication (in $Millions)...................................................................... 74
Chart 2.1.5 Abbott’s Historic Sales by Brand and Indication (in $Millions) .................................................... 75
Chart 2.1.6 Abbott’s Total Clinical Development Activity............................................................................... 76
Chart 2.1.7 Abbott’s Market Forecast in Cardiology (in $Millions) ................................................................. 76
Chart 2.1.8 Abbott’s Strategic Alliances and Mergers...................................................................................... 77
Chart 2.1.9 Abbott’s Summary Cardiology Development Activity vs. Industry............................................... 78
Chart 2.1.10 Abbott’s Cardiology Development Programs by Phase of Development and Technology
Platform......................................................................................................................................... 80
Chart 2.1.11 Abbott’s ACS Pipeline ................................................................................................................... 80
Chart 2.1.12 Abbott’s Arrhythmia Pipeline ........................................................................................................ 81
Chart 2.1.13 Abbott’s Atherosclerosis Pipeline .................................................................................................. 81
Chart 2.1.14 Abbott’s CHF Pipeline ................................................................................................................... 82
Chart 2.1.15 Abbott’s Hypertension Pipeline ..................................................................................................... 83
Chart 2.1.16 Abbott’s Historic and Projected Sales (in $Millions)..................................................................... 83
Chart 2.2.1 AstraZeneca’s US Rx Sales Rank vs. Major Firms (in $Millions)................................................. 84
Chart 2.2.2 AstraZeneca’s Sales Rank In Cardiology (in $Millions)................................................................ 85
Chart 2.2.3 AstraZeneca’s Cardiology Share of Total US Sales....................................................................... 85
Chart 2.2.4 AstraZeneca’s Historic Sales by Indication (in $Millions)............................................................. 86
Chart 2.2.5 AstraZeneca’s Historic Sales by Brand and Major Indication (in $Millions) ................................ 87
Chart 2.2.6 AstraZeneca’s Total Clinical Development Activity...................................................................... 88
Chart 2.2.7 AstraZeneca’s Market Forecast in Cardiology (in $Millions)........................................................ 88
Chart 2.2.8 AstraZeneca’s Strategic Alliances and Mergers............................................................................. 90
Chart 2.2.9 AstraZeneca’s Summary Cardiology Development Activity vs. Industry ..................................... 90
Chart 2.2.10 AstraZeneca’s Cardiology Development Programs by Phase of Development and Technology
Platform......................................................................................................................................... 92
Chart 2.2.11 AstraZeneca’s ACS Pipeline .......................................................................................................... 93
Chart 2.2.12 AstraZeneca’s Atherosclerosis Pipeline ......................................................................................... 94
Chart 2.2.13 AstraZeneca’s CHF Pipeline .......................................................................................................... 94
Chart 2.2.14 AstraZeneca’s Historic and Projected Sales (in $Millions)............................................................ 95
Chart 2.3.1 Aventis’ US Rx Sales Rank vs. Major Firms (in $Millions) .......................................................... 96
Chart 2.3.2 Aventis’ Sales Rank In Cardiology (in $Millions) ......................................................................... 97
Chart 2.3.3 Aventis’ Cardiology Share of Total US Sales ................................................................................ 97
Chart 2.3.4 Aventis’ Historic Sales by Indication (in $Millions)...................................................................... 98
Chart 2.3.5 Aventis’ Historic Sales by Brand and Major Indication (in $Millions).......................................... 99
Chart 2.3.6 Aventis’ Total Clinical Development Activity............................................................................. 100
Chart 2.3.7 Aventis’ Market Forecast in Cardiology (in $Millions) ............................................................... 100
Chart 2.3.8 Aventis’ Strategic Alliances and Mergers .................................................................................... 101
Chart 2.3.9 Aventis’ Cardiology Summary-Cardiology Development Activity vs. Industry.......................... 102
Chart 2.3.10 Aventis' Cardiology Technology Map.......................................................................................... 102
Chart 2.3.11 Aventis’ Cardiology Programs by Phase of Development and Technology Platform.................. 104
Chart 2.3.12 Aventis’ ACS Pipeline ................................................................................................................. 105
Chart 2.3.13 Aventis’ Angina Pipeline ............................................................................................................. 106
Chart 2.3.14 Aventis’ Arrhythmia Pipeline....................................................................................................... 107
Chart 2.3.15 Aventis’ Atherosclerosis Pipeline ................................................................................................ 108
Chart 2.3.16 Aventis’ CHF Pipeline ................................................................................................................. 109
Chart 2.3.17 Aventis’ Hypertension Pipeline.................................................................................................... 109
Chart 2.3.18 Aventis’ Restenosis Pipeline ........................................................................................................ 110
Chart 2.3.19 Aventis’ Historic and Projected Sales (in $Millions) ................................................................... 110
Chart 2.4.1 Bristol-Myers Squibb’s US Rx Sales Rank vs. Major Firms (in $Millions) ................................ 111
Chart 2.4.2 Bristol-Myers Squibb’s Sales Rank In Cardiology Sales (in $Millions) ...................................... 112
Chart 2.4.3 Bristol-Myers Squibb’s Cardiology Share of Total US Sales (in $Millions) ............................... 112
Chart 2.4.4 Bristol-Myers Squibb’s Historic Sales by Indication (in $Millions) ............................................ 113
Chart 2.4.5 Bristol-Myers Squibb’s Historic Sales by Brand and Major Indication (in $Millions) ................ 115
Chart 2.4.6 Bristol-Myers Squibb’s Total Clinical Development Activity ..................................................... 116
Chart 2.4.7 Bristol-Myers Squibb’s Market Forecast in Cardiology (in $Millions) ....................................... 117
Chart 2.4.8 Bristol-Myers Squibb’s Strategic Alliances and Mergers ............................................................ 119
Chart 2.4.9 Bristol-Myers Squibb’s Cardiology Summary of Development Activity vs. Industry................. 120
Chart 2.4.10 Bristol-Myers Squibb’s Cardiology Development Programs by Phase of Development and
Technology Platform.................................................................................................................... 122
Chart 2.4.11 Bristol-Myers Squibb’s ACS Pipeline.......................................................................................... 125
Chart 2.4.12 Bristol-Myers Squibb’s Arrhythmia Pipeline............................................................................... 126
Chart 2.4.13 Bristol-Myers Squibb’s Atherosclerosis Pipeline......................................................................... 126
Chart 2.4.14 Bristol-Myers Squibb’s CHF Pipeline.......................................................................................... 127
Chart 2.4.15 Bristol-Myers Squibb’s Hypertension Pipeline ............................................................................ 128
Chart 2.4.16 Bristol-Myers Squibb’s Restenosis Pipeline ................................................................................ 129
Chart 2.4.17 Bristol-Myers Squibb’s Historic and Projected Sales (in $Millions) ........................................... 130
Chart 2.5.1 GlaxoSmithKline’s US Rx Sales Rank vs. Major Firms (in $Millions)....................................... 131
Chart 2.5.2 GlaxoSmithKline’s Sales Rank In Cardiology (in $Millions)...................................................... 132
Chart 2.5.3 GlaxoSmithKline’s Cardiology Share of Total US Sales............................................................. 132
Chart 2.5.4 GlaxoSmithKline’s Historic Sales by Indication (in $Millions)................................................... 133
Chart 2.5.5 GlaxoSmithKline’s Historic Sales by Brand and Major Indication (in $Millions) ...................... 134
Chart 2.5.6 GlaxoSmithKline’s Total Clinical Development Activity............................................................ 134
Chart 2.5.7 GlaxoSmithKline’s Market Forecast in Cardiology (in $Millions) .............................................. 135
Chart 2.5.8 GlaxoSmithKline’s Strategic Alliances and Mergers................................................................... 136
Chart 2.5.9 GlaxoSmithKline’s Cardiology Summary of Development Activity vs Industry ........................ 137
Chart 2.5.10 Technology Utilization – GlaxoSmithKline vs. Industry ............................................................. 138
Chart 2.5.11 GlaxoSmithKline’s Cardiology Development Programs by Phase of Development and
Technology Platform.................................................................................................................... 139
Chart 2.5.12 GlaxoSmithKline’s ACS Pipeline ................................................................................................ 139
Chart 2.5.13 GlaxoSmithKline’s Atherosclerosis Pipeline ............................................................................... 140
Chart 2.5.14 GlaxoSmithKline’s CHF Pipeline ................................................................................................ 141
Chart 2.5.15 GlaxoSmithKline’s Hypertension Pipeline................................................................................... 142
Chart 2.5.16 GlaxoSmithKline’s Historic and Projected Sales (in $Millions) .................................................. 142
Chart 2.6.1 Merck’s US Rx Sales Rank vs. Major Firms (in $Millions) ........................................................ 143
Chart 2.6.2 Merck’s Sales Rank In Cardiology (in $Millions)........................................................................ 144
Chart 2.6.3 Merck’s Cardiology Share of Total US Sales............................................................................... 144
Chart 2.6.4 Merck’s Historic Sales by Indication (in $Millions) .................................................................... 145
Chart 2.6.5 Merck’s Historic Sales by Brand and Major Indication (in $Millions) ........................................ 147
Chart 2.6.6 Merck’s Total Clinical Development Activity ............................................................................. 148
Chart 2.6.7 Merck’s Market Forecast in Cardiology (in $Millions)................................................................ 149
Chart 2.6.8 Merck’s Strategic Alliances and Mergers..................................................................................... 150
Chart 2.6.9 Merck’s Cardiology Summary Cardiology Development Activity vs. Industry .......................... 150
Chart 2.6.10 Merck’s Cardiology Development Programs by Phase of Development and Technology
Platform....................................................................................................................................... 152
Chart 2.6.11 Merck’s ACS Pipeline.................................................................................................................. 153
Chart 2.6.12 Merck’s Atherosclerosis Pipeline................................................................................................. 153
Chart 2.6.13 Merck’s Hypertension Pipeline .................................................................................................... 154
Chart 2.6.14 Merck’s Historic and Projected Sales (in $Millions).................................................................... 154
Chart 2.7.1 Novartis’ US Rx Sales Rank vs. Major Firms (in $Millions)....................................................... 155
Chart 2.7.2 Novartis’ Sales Rank In Cardiology (in $Millions)...................................................................... 156
Chart 2.7.3 Novartis’ Cardiology Share of Total US Sales............................................................................. 156
Chart 2.7.4 Novartis’ Historic Sales by Indication (in $Millions) .................................................................. 157
Chart 2.7.5 Novartis’ Historic Sales by Brand and Major Indication (in $Millions) ...................................... 158
Chart 2.7.6 Novartis’ Total Clinical Development Activity ........................................................................... 158
Chart 2.7.7 Novartis’ Market Forecast in Cardiology (in $Millions).............................................................. 159
Chart 2.7.8 Novartis’ Strategic Alliances and Mergers................................................................................... 160
Chart 2.7.9 Novartis’ Cardiology Summary Development Activity vs. Industry ........................................... 161
Chart 2.7.10 Novartis’ Cardiology Development Programs by Phase of Development and Technology
Platform....................................................................................................................................... 163
Chart 2.7.11 Novartis’ ACS Pipeline ................................................................................................................ 163
Chart 2.7.12 Novartis’ Angina Pipeline ............................................................................................................ 164
Chart 2.7.13 Novartis’ Arrhythmia Pipeline ..................................................................................................... 164
Chart 2.7.14 Novartis’ CHF Pipeline ................................................................................................................ 165
Chart 2.7.15 Novartis’ Historic and Projected Sales (in $Millions).................................................................. 165
Chart 2.8.1 Pfizer’s US Rx Sales Rank vs. Major Firms (in $Millions) ......................................................... 166
Chart 2.8.2 Pfizer’s Sales Rank in Cardiology (in $Millions)......................................................................... 167
Chart 2.8.3 Pfizer’s Cardiology Share of Total US Sales ............................................................................... 167
Chart 2.8.4 Pfizer’s Historic Sales by Indication (in $Millions) ..................................................................... 168
Chart 2.8.5 Pfizer’s Historic Sales by Brand and Major Indication (in $Millions) ......................................... 169
Chart 2.8.6 Pfizer’s Total Clinical Development Activity .............................................................................. 170
Chart 2.8.7 Pfizer’s Market Forecast in Cardiology (in $Millions) ................................................................ 170
Chart 2.8.8 Pfizer’s Strategic Alliances and Mergers ..................................................................................... 171
Chart 2.8.9 Pfizer’s Cardiology Summary - Development Activity vs. Industry............................................ 172
Chart 2.8.10 Pfizer’s Cardiovascular Development Programs by Phase of Development and Technology
Platform....................................................................................................................................... 174
Chart 2.8.11 Pfizer’s ACS Pipeline................................................................................................................... 175
Chart 2.8.12 Pfizer’s Atherosclerosis Pipeline.................................................................................................. 178
Chart 2.8.13 Pfizer’s CHF Pipeline................................................................................................................... 179
Chart 2.8.14 Pfizer’s Restenosis Pipeline ......................................................................................................... 179
Chart 2.8.15 Pfizer’s Historic and Projected Sales (in $Millions) .................................................................... 180
Chart 2.9.1 Pharmacia’s US Rx Sales Rank vs. Major Firms (in $Millions) .................................................. 181
Chart 2.9.2 Pharmacia’s Sales Rank In Cardiovascular Disease (in $Millions).............................................. 182
Chart 2.9.3 Pharmacia’s Cardiovascular Share of Total US Sales .................................................................. 182
Chart 2.9.4 Pharmacia’s Historic Sales by Indication (in $Millions).............................................................. 183
Chart 2.9.5 Pharmacia’s Historic Sales by Brand and Major Indication (in $Millions).................................. 184
Chart 2.9.6 Pharmacia’s Total Clinical Development Activity....................................................................... 185
Chart 2.9.7 Pharmacia’s Market Forecast in Cardiovascular Disease (in $Millions)...................................... 185
Chart 2.9.8 Pharmacia’s Strategic Alliances and Mergers .............................................................................. 186
Chart 2.9.9 Pharmacia’s Cardiovascular Disease Summary - Development Activity vs. Industry................. 187
Chart 2.9.10 Pharmacia’s Cardiovascular Development Programs by Phase of Development and
Technology Platform.................................................................................................................... 189
Chart 2.9.11 Pharmacia’s Atherosclerosis Pipeline .......................................................................................... 189
Chart 2.9.12 Pharmacia’s CHF Pipeline ........................................................................................................... 190
Chart 2.9.13 Pharmacia’s Hypertension Pipeline.............................................................................................. 191
Chart 2.9.14 Pharmacia’s Restenosis Pipeline .................................................................................................. 191
Chart 2.9.15 Pharmacia’s Historic and Projected Sales (in $Millions) ............................................................. 192
Chart 2.10.1 Roche’s US Rx Sales Rank vs. Major Firms (in $Millions)......................................................... 193
Chart 2.10.2 Roche’s Sales Rank In Cardiovascular Disease (in $Millions) .................................................... 194
Chart 2.10.3 Roche’s Cardiovascular Disease Share of Total US Sales ........................................................... 194
Chart 2.10.4 Roche’s Roche Historic Sales by Indication (in $Millions) ......................................................... 195
Chart 2.10.5 Roche’s Historic Sales by Brand and Major Indication (in $Millions) ........................................ 196
Chart 2.10.6 Roche’s Total Clinical Development Activity ............................................................................. 196
Chart 2.10.7 Roche’s Market Forecast in Cardiology (in $Millions)................................................................ 197
Chart 2.10.8 Roche’s Mergers and Alliances.................................................................................................... 198
Chart 2.10.9 Roche’s Cardiovascular Summary Cardiovascular Disease Development Activity vs. Industry. 199
Chart 2.10.10 Roche’s Cardiovascular Development Programs by Phase of Development and Technology
Platform....................................................................................................................................... 201
Chart 2.10.11 Roche’s ACS Pipeline .................................................................................................................. 201
Chart 2.10.12 Roche’s Atherosclerosis Pipeline ................................................................................................. 202
Chart 2.10.13 Roche’s Hypertension Pipeline .................................................................................................... 202
Chart 2.10.14 Roche’s Historic and Projected Sales (in $Millions).................................................................... 202
Chart 2.11.1 Schering-Plough’s US Rx Sales Rank vs. Major Firms (in $Millions) ........................................ 203
Chart 2.11.2 Schering-Plough’s Sales Rank In Cardiovascular Disease (in $Millions).................................... 204
Chart 2.11.3 Schering-Plough’s Cardiovascular Disease Share of Total US Sales........................................... 204
Chart 2.11.4 Schering-Plough’s Historic Sales by Indication (in $Millions).................................................... 205
Chart 2.11.5 Schering-Plough’s Historic Sales by Brand and Major Indication............................................... 206
Chart 2.11.6 Schering-Plough’s Total Clinical Development Activity............................................................. 206
Chart 2.11.7 Schering-Plough’s Market Forecast in Cardiology (in $Millions) ............................................... 207
Chart 2.11.8 Schering-Plough’s Strategic Alliances and Mergers .................................................................... 208
Chart 2.11.9 Schering-Plough’s Cardiovascular disease Summary – Development Activity vs. Industry ....... 209
Chart 2.11.10 Schering-Plough’s Cardiovascular Development Programs by Phase of Development and
Technology Platform.................................................................................................................... 211
Chart 2.11.11 Schering-Plough’s ACS Pipeline ................................................................................................. 211
Chart 2.11.12 Schering-Plough’s Atherosclerosis Pipeline................................................................................. 212
Chart 2.11.13 Schering-Plough’s Restenosis Pipeline ........................................................................................ 212
Chart 2.11.14 Schering-Plough’s Historic and Projected Sales (in $Millions) ................................................... 213
Chart 2.12.1 Wyeth’s US Rx Sales Rank vs. Major Firms (in $Millions) ........................................................ 214
Chart 2.12.2 Wyeth’s Sales Rank In Cardiology (in $Millions) ....................................................................... 215
Chart 2.12.3 Wyeth’s Cardiology Share of Total US Sales .............................................................................. 215
Chart 2.12.4 Wyeth’s Historic Sales by Indication (in $Millions) .................................................................... 216
Chart 2.12.5 Wyeth’s Historic Sales by Brand and Major Indication ............................................................... 217
Chart 2.12.6 Wyeth’s Total Clinical Development Activity ............................................................................. 218
Chart 2.12.7 Wyeth’s Market Forecast in Cardiology (in $Millions) ............................................................... 218
Chart 2.12.8 Wyeth’s Autoimmune Strategic Alliances and Mergers .............................................................. 219
Chart 2.12.9 Wyeth’s Cardiology Summary Development Activity vs. Industry............................................. 220
Chart 2.12.10 Wyeth’s Cardiology Development Programs by Phase of Development and Technology
Platform....................................................................................................................................... 222
Chart 2.12.11 Wyeth’s ACS Pipeline.................................................................................................................. 222
Chart 2.12.12 Wyeth’s Atherosclerosis Pipeline................................................................................................. 223
Chart 2.12.13 Wyeth’s Historic and Projected Sales (in $Millions) ................................................................... 223